INFORMATION BY CANCER TYPE
The FDA has granted an accelerated approval to Tecentriq as a frontline treatment for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin chemotherapy.
In an interview with CURE, Evan Y. Yu, M.D., discusses the current treatment options for metastatic urothelial carcinoma, the unmet needs that still exist in this space and the possibilities for the future treatment landscape.
In an interview with CURE, Arlene O. Siefker-Radtke, M.D., discusses immune treatment and the immune landscape for the treatment of patients with urothelial cancers.
Charles Drake, M.D., Ph.D.. is optimistic about immunotherapy as it continues to move toward the frontline setting in GU cancers.
The FDA granted avelumab a priority review to a biologics license application to treat some patients with metastatic urothelial carcinoma, according to the developers of the drug.
Cabometyx combinations showed activity in patients with GU cancers, according to a preliminary clinical study.
Patients with metastatic bladder cancer who did not see a benefit on single-agent Opdivo did better when the drug was combined with Yervoy, a recent study showed.
Checkpoint inhibitors drastically changed the treatment landscape of urothelial carcinoma, and more changes are on the way.
The FDA granted Keytruda a priority review for the treatment of some patients with urothelial carcinoma.
Search Cancer Drugs & Terms
Information about treatment, including surgery, chemotherapy, radiation therapy, immunotherapy, and vaccine therapy
Bladder Cancer Treatment (PDQ®)
[ Patients ]
Expert-reviewed information summary about the treatment of bladder cancer.
Gallbladder Cancer Treatment (PDQ®)
[ Patients ]
Expert-reviewed information summary about the treatment of gallbladder cancer.